HUM · NYSE · Medical - Healthcare Plans

Humana (HUM)

Medicare-focused insurer integrating CenterWell pharmacy, primary care and home services.

$371.65
After hours−0.46 (−0.12%)
At close$372.11(−1.71%)
Loading prices…

Humana Inc.HUM
Health Care

Sells Medicare Advantage and prescription-drug plans, Medicaid coverage, military health services and specialty benefits across the United States. CenterWell adds pharmacy, senior primary care and home services, while federal contracts supply most revenue and tie performance to CMS funding and quality rules.

Offers health coverage concentrated in Medicare, alongside Medicaid, military, prescription-drug and supplemental-benefit products. The Insurance segment earns premiums and service fees from individual and group Medicare Advantage plans, stand-alone Part D plans, state-based contracts, TRICARE and specialty benefits across the United States.

Operates CenterWell pharmacy solutions, senior-focused primary care and home solutions for health-plan members and outside payors. The integrated model connects insurance data, owned clinical services and contracted value-based providers to coordinate care and manage medical utilization. Transactions between CenterWell and Insurance make the segments operationally and financially interdependent.

Most premium and service revenue comes from federal government contracts, while Medicare Advantage economics depend on CMS funding, risk adjustment and Star Ratings that determine quality bonuses.

Company facts

CEOJames A. Rechtin
ListedDec 31, 1981
ExchangeNYSE
HeadquartersLouisville, KY
CountryUnited States
Employees67,060
CIK0000049071
ISINUS4448591028

Market cap$45.39B
EPS (ttm)$10.56
P/E (ttm)35.85
ROE6.9%
P/B2.36
P/S0.3116
Dividend yieldDiv yield0.94%
Beta0.54vs XLV 0.51

Price target$415.00+11.8%Average of 44 analysts
ConsensusHold26 of 44 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Aug 24, 2026Wolfe ResearchReiterate
Rating: Target: $498
Rating: OutperformTarget: $450
Aug 5, 2026Morgan StanleyUpgrade
Rating: Underweight
Rating: Equal Weight
Aug 4, 2026Morgan StanleyTarget
Target: $249
Target: $370
Jul 31, 2026BarclaysReiterate
Rating: Target: $344
Rating: Equal WeightTarget: $407
Jul 30, 2026Piper SandlerUpgrade
Rating: NeutralTarget: $254
Rating: OverweightTarget: $463

Next report
Nov 6, 26
estimated · in 45 days
EPS estimate
−$1.04
Revenue estimate
$40.87B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25Apr '25Jul '25Nov '25Feb '26Apr '26Jul '26Nov '26
Reported−$2.16$11.58$6.27$3.24−$3.96$10.31$7.61Pending
Estimate−$2.23$10.07$5.92$2.93−$4.00$10.24$7.27−$1.04
Surprise+3.1%+15.0%+5.9%+10.6%+1.0%+0.7%+4.7%

RevenueReportedEstimate

Feb '25Apr '25Jul '25Nov '25Feb '26Apr '26Jul '26Nov '26
Reported$29.21B$32.11B$32.39B$32.65B$32.52B$39.65B$40.87BPending
Estimate$28.81B$32.20B$31.87B$32.00B$32.04B$39.37B$40.58B$40.87B
Surprise+1.4%−0.3%+1.6%+2.0%+1.5%+0.7%+0.7%
Estimate−$1.04
ReportedDue Nov 6, 2026
Estimate$40.87B
ReportedDue Nov 6, 2026
View details

Debt to equity74.20%
Current ratio174.20%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$29.40B$29.21B$32.11B$32.39B$32.65B$32.52B$39.65B$40.87B
Net income$480.0M−$693.0M$1.24B$545.0M$195.0M−$796.0M$1.19B$693.0M
Net margin1.6%0.0%3.9%1.7%0.6%0.0%3.0%1.7%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$635.0M−$899.0M$1.65B$722.0M$108.0M−$1.03B$1.58B$1.36B
YoY growth−41.5%Loss widened+66.5%−19.9%−83.0%Loss widened−4.2%+88.4%

Balance sheet, Jun 30, 2026Cash & short-term investments $23.87B · Total debt $14.25B · Total assets $57.20B · Shareholders' equity $19.21B

Revenue
$40.87B
Operating income
$1.36B
Net income
$693.0M
View details

Dividend yield
0.94%
Next ex-date
Oct 30, 26
in 38 days
Annual dividend
$3.54
per share
Schedule
Quarterly
4 payments a year

HistoryDividendAnnual yieldUpcoming

Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Oct '26
Dividend$0.885$0.885$0.885$0.885$0.885$0.885$0.885$0.885
Annual yield1.40%1.34%1.46%1.39%1.37%2.09%0.92%0.95%
Ex-dateDec 31Mar 28Jun 27Sep 26Dec 26Mar 27Jun 26Oct 30
Payment dateJan 31Apr 25Jul 25Oct 31Jan 30Apr 24Jul 31Nov 27
View details

Institutions99.77%119.79M shares
993 holders · as of Jun 30, 2026
Insiders0.28%338.4K shares
22 holders · as of Sep 3, 2026
Adds to100.05%

120.06M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 100.05%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
Dodge & CoxInstitution
9.11%10.94Mas of Jun 30, 2026
BlackRock, Inc.Institution
8.68%10.42Mas of Jun 30, 2026
Vanguard Capital Management LLCInstitution
6.53%7.84Mas of Jun 30, 2026
T. Rowe Price Associates, Inc.Institution
5.47%6.57Mfiled Feb 14, 2018
Vanguard Portfolio Management LLCInstitution
4.85%5.82Mas of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Feb 23, 2026Sanjay K. Shettyofficer: President, CenterWell+810$185.21
View details

  • UnitedHealth Group

    Dominant MA insurer with Optum's integrated care and pharmacy platform.

  • CVS Health

    Aetna MA, Oak Street primary care, Signify home health, Caremark PBM.

  • Elevance Health

    Blue Cross MA insurer with Carelon services, growing MA in 2025.

  • Centene

    #1 Medicaid insurer; 1M MA members with highest D-SNP concentration.

  • Molina Healthcare

    Medicaid and D-SNP specialist exiting traditional MA in 2027.

  • Cigna

    PBM powerhouse via Evernorth/Express Scripts; exited MA March 2025.

CompareAfter hours

CompanyPriceChange
Humana$371.65−0.12%$45.39B35.930.20.3+26.2%
UnitedHealth Group$373.03+0.03%$342.88B24.317.50.8+0.4%
CVS Health$87.14+0.06%$111.77B23.210.80.3+7.3%
Elevance Health$401.00−0.32%$88.77B18.214.80.4+0.8%
Centene$63.30+0.02%$32.10B14.00.2+9.9%
Molina Healthcare$191.15−0.03%$10.33B1,041.127.10.2−4.8%
Cigna$274.02+0.08%$72.53B11.48.60.3+6.6%
Median23.214.40.3+3.7%